TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension.
about
Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markersANG II increases TIMP-1 expression in rat aortic smooth muscle cells in vivoEffects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathyArrhythmia and neuronal/endothelial myocyte uncoupling in hyperhomocysteinemiaMatrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis.Membrane-associated matrix proteolysis and heart failure.H2S ameliorates oxidative and proteolytic stresses and protects the heart against adverse remodeling in chronic heart failureUse of biomarkers of collagen types I and III fibrosis metabolism to detect cardiovascular and renal disease in chimpanzees (Pan troglodytes)Plasma tissue inhibitor of matrix metalloproteinase-1 (TIMP-1): an independent predictor of poor response to cardiac resynchronization therapyMMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure.The effect of antihypertensive treatment on arterial stiffness and serum concentration of selected matrix metalloproteinases.Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction.Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality.Time course of early changes in plasma markers of collagen turnover following percutaneous transluminal coronary angioplastySynergism between arrhythmia and hyperhomo-cysteinemia in structural heart disease.Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced by angiotensin II.The increasing impact of laboratory medicine on clinical cardiology.Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programmeReversal of systemic hypertension-associated cardiac remodeling in chronic pressure overload myocardium by ciglitazone.Role of MMP-2 and MMP-9 in resistance to drug therapy in patients with resistant hypertension.Physical versus psychological social stress in male rats reveals distinct cardiovascular, inflammatory and behavioral consequencesHypertensive myocardial fibrosis.Relations of matrix remodeling biomarkers to blood pressure progression and incidence of hypertension in the community.Cardiac fibrosis in mouse expressing DsRed tetramers involves chronic autophagy and proteasome degradation insufficiency.Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.Molecular and cellular basis for diastolic dysfunction.Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease.Wnt5a is elevated in heart failure and affects cardiac fibroblast function.Biochemical evidence of myocardial fibrosis in veteran endurance athletes.Tipping the extracellular matrix balance during heart failure progression: do we always go right?Effect of QiShenYiQi Pill on Myocardial Collagen Metabolism in Rats with Partial Abdominal Aortic Coarctation.Improvement in collagen metabolism after 12 weeks' cardiac resynchronization therapy in patients with ischaemic cardiomyopathy.Protease-activated receptor and endothelial-myocyte uncoupling in chronic heart failure.Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure.Dynamic assessment of myocardial involvement in patients with end-stage renal disease by ultrasonic tissue characterization and serum markers of collagen metabolism.Left ventricular diastolic dysfunction in newly diagnosed untreated hypertensive patients.Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study.Overexpression of TIMP-1 in embryonic stem cells attenuates adverse cardiac remodeling following myocardial infarction.Circulating levels of a biomarker of collagen metabolism are associated with health-related quality of life in patients with chronic heart failure.Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?
P2860
Q24644869-137774F8-58A8-470C-8482-9FAAA1D98642Q28565557-AC3B83A4-EAE6-4EC1-93A8-0F08F2E34348Q28742534-7CDA5C5A-BA5F-4577-AD01-D01AD9EB05D4Q28744457-55045421-059B-4634-9D94-91E01612D3BDQ31121727-E57264A1-7E8A-4311-97F6-A03ED1885F71Q33632033-B777DCF2-37B1-48A4-AEB1-4CB2404B1040Q33655952-DD999778-77F5-4600-812D-3BA1CBD6D09EQ33791183-79159F8A-0E6C-422F-8BEE-7C06CC98E2C6Q33803826-6FEBE30D-9857-4DBD-8BF7-13A8AADD8A36Q33887793-BC6E2324-EDDD-47D8-AB16-96554A18A939Q33904413-F058F618-B467-4F14-9161-747C3FDD8C6BQ34138706-7C7F9ECE-C948-45A4-B292-1C16E4843CFEQ34222299-76AEEBF0-6044-405B-A7C8-BD2799C861F1Q34338635-8C79602D-B584-4A0A-80BB-9DB0359ADA0BQ35098436-786274CA-99B5-4D85-9722-DAC7C572527EQ35152779-094705A1-1705-497F-9970-78BC6EE7CB25Q35206514-C3D0BED7-1AFB-44F8-82A4-C34F45742067Q35772957-02647A17-5C6D-4B1B-A178-C3937CD9CDB0Q35989215-6E9E4311-9610-419B-802A-5D382427FA26Q36024251-E72A0C28-F74B-47CF-A516-FB09C3F0094FQ36291589-C2651A54-A06A-4066-8E86-2103C1430C7EQ36303503-E1825D4C-5464-4F0C-91F1-73EEAC6656A7Q37312630-42753D90-BC22-445A-AC84-8060A7D536A2Q37688051-11688148-B582-47E1-9188-18B79D347E4CQ37895982-CF76E430-F17B-468B-B1F8-455A3B67D31EQ38038531-4CFE9791-C765-47A0-8B9C-EE536EF3A6A8Q38040163-E74DE05C-D372-4D51-91EA-FFAD46397917Q40272717-CFBDDAB2-EC9E-4382-B007-666A85DBA76BQ40300916-865F6065-1981-4445-9A5B-2EA15E63EE47Q42531345-60222BED-864B-4123-A839-1FF6CD29585AQ42678247-6F910B94-7514-4674-A66D-24858BA9F2D5Q44914311-6E2C68CB-5776-4193-8E06-B86111D97939Q45244992-E4D33284-D2AD-4ED6-BCBF-956CCE9C8BABQ46705065-A112D6AF-2784-4031-BA13-6A10710B3E50Q47668936-94FED162-96D5-4062-B9AB-2DDE39806504Q47744683-41DBEE93-E248-43A4-8390-8E90639A66B4Q47960038-5380F963-8B58-4CA2-BFA3-974CAFEB0847Q47980596-FE4E9A87-414E-4ECA-9D2A-88BB406F18AAQ48666150-1B30AEF3-849A-40A1-B392-983BCDF3B82AQ49106557-DF5B7EB5-A5F0-480C-A860-755E26FC442A
P2860
TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension.
@en
TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension.
@nl
type
label
TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension.
@en
TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension.
@nl
prefLabel
TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension.
@en
TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension.
@nl
P2093
P1433
P1476
TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension.
@en
P2093
Francis G Dunn
M Mitchell Lindsay
Paul Maxwell
P304
P356
10.1161/01.HYP.0000024573.17293.23
P407
P577
2002-08-01T00:00:00Z